Correction to: Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.
- Published in:
- 2018
- By:
- Publication type:
- Correction Notice
Works matching IS 11707690 AND DT 2018 AND VI 36 AND IP 7
Results: 13
1
2
Cost Effectiveness of Secukinumab for the Treatment of Active Psoriatic Arthritis in the UK.
- Published in:
- 2018
- By:
- Publication type:
- journal article
3
Discounting in Economic Evaluations.
- Published in:
- 2018
- By:
- Publication type:
- journal article
4
Should Low- and Middle-Income Countries Adopt Clinical Guidelines Developed in 'Rich' Countries?
- Published in:
- 2018
- By:
- Publication type:
- Editorial
5
Comment on: "A Systematic Review of the Cost-Effectiveness of Biologics for Ulcerative Colitis".
- Published in:
- 2018
- By:
- Publication type:
- Letter
6
Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
- Published in:
- 2018
- By:
- Publication type:
- journal article
7
Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.
- Published in:
- 2018
- By:
- Publication type:
- journal article
8
The Role of Measurement Uncertainty in Health Technology Assessments (HTAs) of In Vitro Tests.
- Published in:
- 2018
- By:
- Publication type:
- journal article
9
The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review.
- Published in:
- 2018
- By:
- Publication type:
- journal article
10
Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England.
- Published in:
- 2018
- By:
- Publication type:
- journal article
11
Ponatinib for Treating Acute Lymphoblastic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2018
- By:
- Publication type:
- journal article
12
Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
- Published in:
- 2018
- By:
- Publication type:
- journal article
13
Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?
- Published in:
- 2018
- By:
- Publication type:
- journal article